

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):


- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)

PRV SE 99/00347

PATENT- OCH REGISTRERINGSVERKET
PatentavdelningenIntyg
Certificate

Härmed intygas att bifogade kopior överensstämmer med de handlingar som ursprungligen ingivits till Patent- och registreringsverket i nedannämnda ansökan.

This is to certify that the annexed is a true copy of the documents as originally filed with the Patent- and Registration Office in connection with the following patent application.

(71) Sökande Scotia LipidTeknik AB, Stockholm SE
Applicant (s)

(21) Patentansökningsnummer 9800729-7
Patent application number

(86) Ingivningsdatum 1998-03-06
Date of filing

Stockholm, 1999-03-31

För Patent- och registreringsverket
For the Patent- and Registration Office

Emma Johnsson

Emma Johnsson

Avgift
Fee

PRIORITY DOCUMENT

NEW TOPICAL FORMULATION I

The present invention refers to a topical formulation of the oil-in-water emulsion type, in which a variety of pharmaceutical or cosmetic compounds can be incorporated, and which after application on the skin gives a sustained local effect of the incorporated compound.

BACKGROUND OF THE INVENTION

Dermatological formulations for topical administration, such as creams, lotions, ointments and gels, are used in pharmacy, medicine and cosmetics for curative and prophylactic treatment of different conditions. It is in general desirable that said formulation brings about a sustained effect.

There are different areas where there is a continuous need of an improved, that is sustained, topical treatment as exemplified below.

- People who frequently are exposed to water and soap often develop dry skin conditions and need to apply a protective cream or ointment to their skin. Examples are doctors and nurses who must wash their hands and face before examining patients, workers who are handling paints and grease and often need to use strong detergents to clean their hands, and, most common of all, home workers. For these and other categories of people having dry skin conditions a cream or lotion with an extended effect on skin smoothing and moisturising would be preferred.

- The use of hydrocortisone and other steroidal creams is very common in the treatment of local inflammatory conditions in the skin. The systemic absorption of the steroid decreases the local effect and potentially gives unwanted side-effects. A cream with a sustained release of the active steroid would increase the local effect and decrease the systemic absorption, a very much preferred therapeutic situation, especially in small children.

- The treatment of Athlete's foot or other fungal infections with topical antifungal or of many skin infec-

tions with antibiotics or antivirals requires twice or three times daily applications of the cream or gel to be effective. A once-daily formulation would certainly improve compliance, effectiveness, as well as comfort during treatment.

- The treatment of any other skin condition, including psoriasis, eczemas, other inflammatory disorders, cancers, precancerous conditions, aging, wrinkling, ultraviolet radiation damage and any other condition which may respond to a topically applied therapeutic agent.

Preferred topical formulations are creams and lotions, that is typically oil-in-water emulsions which spread readily on the skin, leave no detectable residue and adhere to the treated area without being tacky. Said emulsions normally consist of an oil phase, an aqueous phase and an emulsifier. Ointments, which mainly comprises an oil phase, are greasy and form a greasy film on the skin preventing moisture loss. Gels which might be liposomal preparations do not contain any oil. Topical preparations of the oil-in-water emulsion type are generally more appreciated by the user from a cosmetic point of view, but have not previously been claimed to give any extended effect of incorporated substances of dermatological or cosmetological interest. From a dermatological standpoint oil-in-water emulsion type formulations are often preferred, particularly if the number of ingredients can be reduced to a minimum.

PRIOR ART

Highly structured vehicles, such as inversed hexagonal and cubic liquid crystals, may exhibit sustained-release properties, either by binding the water or by stiffening the amphiphilic film within the formulation, see Osborne, D.W., et al. in Drugs and the Pharmaceutical Sciences, Swarbrick J.(ed.), Vol. 42 (1990), pp. 374-379. Drug formulations containing liposomes for topical use may give a sustained local effect of the incorporated compound, see Kortling, H.C., et al. in J. Am. Acad. Dermatol., Vol. 25 (1991), pp. 1068-1071. The topical drug delivery systems described are, however, far more complicated lipid preparations than a

topical cream of the oil-in-water emulsion type. For reasons of stability of topical liposomal systems, most authors have proposed a gel base. Gel formulations are, however, more likely to produce side effects than cream or ointment preparations.

5 WO 95/03784, Insite Vision Inc., discloses a cross-linked polymeric medicament delivery system containing an interactive agent associated with the polymer, which is said to slow release of medicament out of the system. The system can be used in dermal formulations but is particularly use-
10 ful as topical ophthalmic delivery systems. This invention does not relate to any slow release effects of the cream, but on polymeric systems included in the cream. The slow release effects in this system can be ascribed to the poly-
15 meric system.

15 Topical creams of the oil-in-water emulsion type have not previously been reported as having potential sustained release properties. However, there is a need for topical sustained release formulations, such as oil-in-water emulsions, which are uncomplicated with respect to
20 compositional design as well as manufacturing. Furthermore, less complicated formulations have a major advantage in that they are less likely to cause irritant or hypersensitivity reactions and hence to be more acceptable as skin care preparations for therapeutic or cosmetic use.

25 WO 95/20943, Karlshamns LipidTeknik AB, discloses an oil-in-water emulsion comprising 0.01-50 % by weight of a galactolipid material as an emulsifier. Said emulsion is said to be useful as a carrier for active substances in a pharmaceutical composition but also in nutritional, cos-
30 metic, food and agricultural products. The emulsions do not exhibit any unpleasant odour or taste and are stable towards oxidation. There is, however, nothing stated about an optional sustained effect.

35 DESCRIPTION OF THE INVENTION

The present invention relates to an oil-in-water emulsion for topical application to the skin comprising an

emulsifier, an oil phase, and an aqueous phase, into which cosmetic or pharmaceutical substances can be incorporated for the local treatment of various skin conditions and disorders.

5 It has surprisingly been found that a topical cream or lotion of the oil-in-water emulsion type, in which a galactolipid material is used as the emulsifier, and into which a variety of pharmaceutical or cosmetic compounds can be incorporated, after application on the skin gives a sustained local effect of the incorporated compound.

10 The present invention refers to a topical formulation of the oil-in-water emulsion type, in which a variety of pharmaceutical or cosmetic compounds can be incorporated, comprising an oily material, an emulsifier being a glycolipid based material, and an aqueous phase, and which after
15 application on the skin gives a sustained local effect of the incorporated compound.

According to another aspect the invention refers to the use of a topical formulation of the oil-in-water type comprising an oily material, an aqueous phase and an emul-
20 sifier, wherein the emulsifier is a galactolipid material, as a carrier for providing a sustained effect of an incorporated active substance.

Especially the invention refers to the use of a topical formulation, which can be a cream or a lotion, comprising
25 0.1-50 % by weight oily material, preferably 1-40 %, and 0.5-20 % by weight emulsifier.

No particular limitation is imposed on the oily material, that is the non-polar lipid material, of the formulation. Examples are vegetable oils, animal oils, fatty acids,
30 synthetic oils, mineral oils, natural and synthetic glycerides, sterol esters, fatty alcohols, and other substances, including lipophilic drugs, obvious to a person skilled in the art, which can be emulsified using a polar lipid emulsifier.

35 Preferred oily materials to be emulsified are any fatty acid or a derivative thereof, such as vegetable oils of all types, such as oils from the seeds and beans of soybean,

sunflower, rapeseed (canola), palm, corn, evening primrose, borage, groundnut, sesame, and similar.

There are also synthetic or semi-synthetic glycerides, propanediol derivatives, cholesteryl esters, other esters and other appropriate lipid materials. Another oily material
5 for the emulsion is a medium-chain triacylglycerol (MCT) oil.

There are also many lipids such as free fatty acids, mono-, di- and triacylglycerols, phospholipids, cholesterol esters and lipids and oils of many other types which have
10 therapeutic actions in themselves, such as tea tree oil, and which may be advantageously formulated in the form of a topical cream or optionally lotion. In this case the therapeutically active substance is the oily material, which can also have other bioactive properties.

15 The emulsifier according to the invention should be a glycolipid, preferably a galactolipid based material. Galactolipids can be defined as glycosylglycerides based on galactose and are well known constituents of plant cell membranes. The most important classes of these contain one to
20 four sugars linked glycosidically to diacylglycerol. The two most abundant classes contain one and two galactose units, respectively, and are commonly known as mono- and digalactosyldiacylglycerol, MGDG and DGDG. Galactolipids, primarily DGDG and DGDG-rich materials, have been investigated and
25 found to be a surface active material of interest in industrial application such as food, cosmetics, and pharmaceutical applications.

Synthetic diglycosyldiacylglycerols based on galactose, optionally in combination with other monosaccharide units,
30 such as glucose, semi-synthetic, and natural glycosylglycerides, isolated from any source, can be used in accordance with the invention.

An intrinsic beneficial feature of the galactolipids is the galactose units comprising the polar head group in each
35 lipid molecule, which may sterically stabilise the emulsion droplets in an emulsion. The galactose groups may also interact strongly with water and other polar substances, such

as a water-soluble drug or a excipient, added to the emulsion.

WO 95/20943 describes the use of DGDG-rich material, a galactolipid material, as an emulsifier in oil-in-water emulsions. Said galactolipid material was prepared from cereals by extraction of the lipids with ethanol and a subsequent purification on a chromatographic column to pure DGDG or a DGDG-rich fraction of polar lipids. The galactolipid emulsifier consists of at least 50 % digalactosyldiacylglycerols and a remainder of other polar lipids and can be used as the galactolipid emulsifier of the invention, preferably in an amount of 1.0-5.0 % by weight. The galactolipid material for instance consists of 70-80 % DGDG and 20-30 % other polar lipids.

According to a preferred embodiment of the invention the galactolipid emulsifier consists of 50-70 % digalactosyldiacylglycerols and 30-50 % other polar lipids. This material is manufactured by Scotia LipidTeknik AB, Stockholm, as CPL®-Galactolipid (registered trade mark owned by Scotia Holdings plc). A preferred topical formulation of the invention comprises CPL®-Galactolipid as the galactolipid material.

WO 97/11141 describes a method for producing a fractionated vegetable oil which is characterised in containing 10-90 % by weight of polar lipids, preferably 20-75 %, and a remainder of non-polar lipids. Said fractionated vegetable oil can also be used as the galactolipid emulsifier of the invention, preferably in an amount of 2.0-10.0 % by weight. The fractionated vegetable oil preferably contains more than 5 % by weight, preferably more than 20 %, glycolipids and preferably more than 3 % by weight, preferably more than 15 %, DGDG.

According to a preferred embodiment of the invention the galactolipid material consists of 40-60 % polar lipids and a remainder of non-polar lipids. A fractionated oat oil of this composition consisting of a wide range of polar and amphiphilic lipids in a continuous triglyceride phase is manufactured by Scotia LipidTeknik AB, Stockholm, as

GalactolecTM. A preferred topical formulation comprises GalactolecTM as the galactolipid material.

The galactolipid based emulsifier is a safe and non-toxic material for human and veterinary use. It is also an environmentally friendly material.

5 Topical formulations, such as creams and lotions, are prepared by using a polar lipid emulsifier either as the sole emulsifier or in combination with other amphiphilic compounds, that is co-surfactants. The formulation may also
10 comprise optional additives known in the art for improving different aspects of the composition, such as thickening agents, preservatives, antioxidants, fragrance and the like.

 The creams according to the invention are characterised by having excellent cosmetic properties. Furthermore, they contain a minimum number of ingredients, without any
15 stabilising ingredients known to give irritation or sensitisation of the skin.

 The active substances can be either water soluble or oil soluble or amphiphilic, and can be any type of pharmaceutical or cosmetological ingredient suitable for topical
20 preparations, such as vitamins, e.g. retinol and tocopheryl esters, anti-inflammatories, e.g. hydrocortisone, betamethasone, etc., antibiotics, e.g. erythromycin, antivirals, e.g. acyclovir, antifungals, e.g. miconazole, antiseptics, e.g. cetrimide, agents for treating acne, e.g. tretinoin,
25 benzylperoxide, psoriasis, e.g. dithranol, senile pruritus, dry skin and wrinkles, cancer and pre-cancerous conditions, such as actinic keratosis, and UV protecting agents to be included in suntan creams and lotions.

 Topical creams according to the invention are prepared
30 by conventional methods. For example, a cream with 20 % by weight of oil is prepared by adding the emulsifier to a triacylglycerol oil. The oil phase may also contain oil-soluble additives such as antioxidants and fragrance. The total emulsifier concentration is 1.5 % by weight. The oil
35 phase is then gently mixed. The continuous phase may be pure water or an aqueous solution containing water-soluble

additives such as glycerol, preservatives and buffers. A water-soluble active compound, such as glycerol as a moisturiser, may then be added to the aqueous phase; consequently, an oil-soluble compound such as 13-hydroxy-9,11-octadecadienoic acid (13-HODE) is added to the oil phase. Hydrocortisone, an anti-inflammatory drug which is insoluble in both water and oil, may be dispersed in either the aqueous phase or the oil phase. Alternatively, the drug may also be added to the final cream in an extemporaneous preparation. If necessary, the pH of the aqueous phase is adjusted. The oil phase as well as the aqueous phase are preheated to 70°C and then the oil phase is added to the aqueous phase under high-shear mixing. The pre-emulsion is then subjected to homogenisation at 200 psi. After cooling, the cream is transferred to suitable containers.

Formulations, that is creams and lotions, having the following, preferred compositions can be prepared accordingly:

Topical cream base giving an incorporated substance a sustained effect, comprising in % by weight

| | |
|-------------------------|-------------|
| Oily material | 10.0-30.0 % |
| Galactolipid emulsifier | 0.5-5 % |
| Thickener | 2.0-10.0 % |
| Preservative | 0.1-1.0 % |
| Water | ad 100 % |

Topical formulation having a sustained moisturising effect, comprising in % by weight

| | |
|-------------------------|-------------|
| Glycerol | 1.0-5.0 % |
| Oily material | 10.0-30.0 % |
| Galactolipid emulsifier | 0.5-5 % |
| Thickener | 2.0-10.0 % |
| Preservative | 0.1-1.0 % |
| Water | ad 100 % |

Topical formulation having a sustained anti-inflammatory effect, comprising in % by weight

| | | |
|---|-------------------------|-------------|
| | Hydrocortisone | 0.5-1.5 % |
| | Oily material | 10.0-30.0 % |
| 5 | Galactolipid emulsifier | 0.5-5 % |
| | Thickener | 2.0-10.0 % |
| | Preservative | 0.1-1.0 % |
| | Water | ad 100 % |

10 Topical formulation having a sustained anti-psoriatic effect, comprising in % by weight

| | | |
|----|--------------------------|-------------|
| | 13-hydroxy-linoleic acid | 0.001-0.1 % |
| | Oily material | 10.0-30.0 % |
| | Galactolipid emulsifier | 0.5-5 % |
| 15 | Thickener | 2.0-10.0 % |
| | Preservative | 0.1-1.0 % |
| | Water | ad 100 % |

20 Different topical formulations with various non-polar oils as the cream base were formulated as described in Examples 1-7. Typical batch sizes are 0.5 to 1 kg. All concentrations are expressed in percent by weight.

EXAMPLES OF FORMULATIONS

25 Example 1. Moisturising cream

| | | | |
|----|-------------------------------|----------|---------------|
| | Oil phase: | | |
| | CPL®-Soybean oil | 20.0 % | Oily material |
| | Cetostearyl alcohol | 7.0 % | Thickener |
| | Glyceryl monostearate/citrate | 2.0 % | Thickener |
| 30 | Emulsifier: | | |
| | CPL®-Galactolipid | 1.5 % | |
| | Aqueous phase: | | |
| 35 | Glycerol | 2.0 % | Moisturiser |
| | Methyl-p-hydroxybenzoate | 0.54 % | Preservative |
| | Propyl-p-hydroxybenzoate | 0.06 % | Preservative |
| | Water | ad 100 % | |

40 The oil and CPL®-Galactolipid were mixed in a beaker and then stirred with a magnetic stirrer until the galactolipid material had dispersed, that is for 30-60 min. The aqueous

phase was mixed in another beaker and stirred with a magnetic stirrer. When the oil phase was homogeneous glyceryl monostearate/citrate and cetostearyl alcohol were added. The oil phase and the aqueous phase were both heated to 65-70°C while stirring. The warm oil phase was added to the warm aqueous phase during high-shear mixing (Polytron PT-MR 3000). After addition of the oil phase the pre-emulsification (high-shear mixing) continued for 2 minutes at 15,000 rpm. The pre-emulsion was then homogenised 2 times at 200 psi in an Ultrasonic homogeniser (Branson Minisonic 4). The cream was allowed to cool in a water bath.

Example 2. Moisturising lotion

| | | |
|-------------------------------|--------|---------------|
| Oil phase: | | |
| CPL®-Evening Primrose oil | 12.0 % | Oily material |
| Cetostearyl alcohol | 2.0 % | Thickener |
| Glyceryl monostearate/citrate | 2.0 % | Thickener |

| | | |
|-------------------|-------|--|
| Emulsifier: | | |
| CPL®-Galactolipid | 1.0 % | |

| | | |
|--------------------------|----------|--------------|
| Aqueous phase: | | |
| Glycerol | 2.0 % | Moisturiser |
| Methyl-p-hydroxybenzoate | 0.54% | Preservative |
| Propyl-p-hydroxybenzoate | 0.06% | Preservative |
| Fragrance | 0.1 % | |
| Water | ad 100 % | |

The lotion was prepared in the same way as the cream in Example 1, that is CPL®-Evening Primrose Oil, CPL®-Galactolipid and ascorbyl palmitate were mixed in a beaker and stirred until the galactolipid material had dispersed properly, that is for 30-60 minutes. The rest of the ingredients was added to the oil phase which was then heated to 70°C. The aqueous phase was prepared in another beaker and heated to 70°C. The oil phase was added to the aqueous phase during high-shear mixing. After addition of the oil phase the high-shear mixing, that is pre-emulsification, continued for 2 min at 15,000 rpm. The pre-emulsion was homogenized twice at 200 psi in an Ultrasonic homogeniser (Branson Minisonic 4). The lotion was allowed to cool in a water bath. The fragrance was added to the cool, that is 35°C, lotion.

Example 3. Moisturising cream

Oil phase:

| | | | |
|---|-------------------------------|--------|---------------|
| | CPL®-Evening Primrose oil | 20.0 % | Oily material |
| | Cetostearyl alcohol | 7.0 % | Thickener |
| 5 | Glyceryl monostearate/citrate | 2.0 % | Thickener |
| | Ascorbyl palmitate | 0.02% | Antioxidant |

Emulsifier:

| | | |
|----|-------------|-------|
| 10 | Galactolec™ | 3.0 % |
|----|-------------|-------|

Aqueous phase:

| | | | |
|----|--------------------------|----------|--------------|
| | Glycerol | 2.0 % | Moisturiser |
| | Methyl-p-hydroxybenzoate | 0.63% | Preservative |
| 15 | Propyl-p-hydroxybenzoate | 0.07% | Preservative |
| | Water | ad 100 % | |

The cream was prepared as described in Example 1.

The cream had the following appearance in the microscope. Small regular to irregular droplets of uniform size evenly distributed in the sample. The average droplet size, estimated by comparison with a ruler installed in the microscope, was found to be in the range of 5-10 μm .

Example 4. Cream base

Oil phase:

| | | | |
|----|-----------------------|--------|---------------|
| 25 | Olive oil | 20.0 % | Oily material |
| | Cetostearyl alcohol | 7.0 % | Thickener |
| 30 | Glyceryl monostearate | 2.0 % | Thickener |

Emulsifier:

| | | |
|--|-------------------|-------|
| | CPL®-Galactolipid | 1.0 % |
|--|-------------------|-------|

Aqueous phase:

| | | | |
|----|------------------------------|-------------|--------------|
| 35 | Methyl-p-hydroxybenzoate | 0.54 % | Preservative |
| | Propyl-p-hydroxybenzoate | 0.06 % | Preservative |
| | Tri-sodium citrate dihydrate | 0.035% | pH-modifier |
| | Citric acid (aq.) | q.s. pH 3.5 | pH-modifier |
| | Water | ad 100 % | |

40 The cream was prepared as described in Example 1.

Example 5. Cream base

Oil phase:

| | | | |
|----|-------------------------------|--------|---------------|
| 45 | Medium-chain triglyceride oil | 10.0 % | Oily material |
| | Cetostearyl alcohol | 7.0 % | Thickener |
| | Glyceryl monostearate | 2.0 % | Thickener |

Emulsifier:
CPL®-Galactolipid 1.0 %

5 Aqueous phase:
Methyl-p-hydroxybenzoate 0.18 % Preservative
Propyl-p-hydroxybenzoate 0.02 % Preservative
Water ad 100 %

The cream was prepared as described in Example 1.

10

Example 6. Anti-inflammatory cream

Oil phase:
15 Hydrocortisone 1.0 % Active substance
CPL®-Evening Primrose oil 20.0 % Oily material
Cetostearyl alcohol 7.0 % Thickener
Glyceryl monostearate 2.0 % Thickener
Ascorbyl palmitate 0.02 % Antioxidant

20 Emulsifier:
CPL®-Galactolipid 1.5 %

Aqueous phase:
25 Glycerol 2.0 % Moisturiser
Methyl-p-hydroxybenzoate 0.63 % Preservative
Propyl-p-hydroxybenzoate 0.07 % Preservative
Water ad 100 %

30 Hydrocortisone was added to the mixture of oil and galactolipid. Otherwise the cream was prepared as described in Example 1.

Example 7. Anti-psoriatic cream

Oil phase:
35 13-HODE 0.01 % Active substance
CPL®-Evening Primrose oil 20.0 % Oily material
Cetostearyl alcohol 7.0 % Thickener
Glyceryl monostearate 2.0 % Thickener
Ascorbyl palmitate 0.02 % Antioxidant

40 Emulsifier:
CPL®-Galactolipid 1.5 %

45 Aqueous phase:
Methyl-p-hydroxybenzoate 0.63 % Preservative
Propyl-p-hydroxybenzoate 0.07 % Preservative
Water ad 100 %

A small amount, about 5 %, of the oil mixture was added to 13-HODE (13-hydroxy-linoleic acid, from Scotia Pharma-

ceuticals Ltd, Carlisle). This mixture was not heated like the rest of the oil phase and was added separately during the pre-emulsification step. Otherwise the cream was prepared as in Example 1.

5 EXPERIMENTAL TEST

Tests of skin smoothing and moisturising properties.

The aim of the studies was to evaluate the moisturising and smoothing properties of creams of the invention after use twice daily for 14 days. Twenty healthy female
10 volunteers aged 18 to 60 years were studied.

The test creams had the following compositions:

| | | Cream A | Cream B | Cream C |
|----|---------------------------|----------|----------|----------|
| | Oil phase: | | | |
| 15 | CPL®-Evening Primrose oil | 20.0 % | 20.0 % | 20.0 % |
| | Cetostearyl alcohol | 7.0 % | 7.0 % | 7.0 % |
| | Ascorbyl palmitate | 0.02 % | 0.02 % | 0.02 % |
| | Emulsifier: | | | |
| 20 | CPL®-Galactolipid | 0.75 % | 0.75 % | 1.5 % |
| | Aqueous phase: | | | |
| | Glycerol | - | 2.0 % | 2.0 % |
| | Methyl-p-hydroxybenzoate | 0.54 % | 0.54 % | 0.63 % |
| 25 | Propyl-p-hydroxybenzoate | 0.06 % | 0.06 % | 0.07 % |
| | Water | ad 100 % | ad 100 % | ad 100 % |

All creams were prepared in the following way: The CPL®-Evening Primrose oil, CPL®-Galactolipid and ascorbyl
30 palmitate were mixed in a beaker and then stirred with a magnetic stirrer until the galactolipid was completely dispersed, that is for 30-60 min. The aqueous phase was mixed in another beaker and stirred with a magnetic stirrer. When the oil phase was homogeneous, cetostearyl alcohol was
35 added. The oil phase and the aqueous phase were both heated to 55°C while stirring. The warm oil phase was added to the warm aqueous phase during high-shear mixing (Polytron PT-MR 3000). After addition of the oil phase the pre-emulsifi-
40 cation continued for 2 min at 15,000 rpm. The pre-emulsion was then homogenised 6 times at 200 psi in an Ultrasonic homogeniser (Branson Minisonic 4). The cream was allowed to

cool in a water bath.

On the first day of the study the subjects were instructed as to the proper manner of application of the products. The creams were then applied by the subjects at home once in the morning and once in the evening as part of the daily body care routine.

An amount approximating the usual applied amount of skin care cream (one fingertip full, approximately 0.2 mL) was taken from the respective container, applied to the test fields noted on the container and rubbed in with the finger. The test fields were not marked during the application period. In order to locate the test fields, the inside of the forearm was optically divided into thirds. The middle third was defined as the lower test field and the upper third as the upper test field. An area the width of two fingers was left free between the two test fields on the underarm. A field on the inside of the upper arm served as the upper test field. The subjects were given a stencil to simplify locating the boundary between the lower and middle field on each arm.

The subjects were instructed that the finger used to apply the creams had to be carefully cleaned with a dry cloth between applications to avoid mixing of the test preparations.

Skin moisture was assessed using a device for determining the capacitance of the skin surface (Corneometer CM 820, Courage & Khazaka, Cologne). The capacity of a conductor (the more or less moist stratum corneum on the skin surface) to store an electric charge is recorded using this method. The instrument probe was held onto the skin without pressing for a brief, defined interval. Five measurements were made per test field. The mean of the five measurements was recorded on-line.

Following the measurement of skin moisture, a negative replica of the skin was made using 2-component silicone rubber impression material (Xantopren® L, Fa. Bayer Dental, Leverkusen, Germany). The subjects laid the stretched but relaxed arms on special arm rests with the inner surface

facing upwards. A surface of approximately 8 x 8 cm in the centre of the test fields was thinly covered with the impression mass mixed with hardener. Approximately 3 min were required for setting. The replicas were peeled off after 8 min. Labels were pressed into the lower edge of the hardening mass. These serve for identification as well as marking of the alignment.

The surface of the silicone replicas was scanned using a Hommel-Tester T2000 (Hommelwerke, Schwenningen, Germany). The path and speed of scanning were controlled over the software. The surface was characterised by the roughness parameter $R_{Z(DIN)}$. Each replica was measured in a star-shaped fashion in 12 directions (30° angles).

Skin moisture was measured and replicas taken immediately before the first application of treatments (baseline) and on study days 15, 16 and 17. The measurements on day 15 were performed 12 to 16 hours after the last application. The measurements on day 16 and 17 were performed 36 to 40 h and 60 to 64 h, respectively, after the last application. The silicone replicas were made directly following the corneometer measurements. The results are presented in Table 1 and 2.

Cream A did not lead to any improvement at all in skin moisture. The incorporation of an active moisturising agent (glycerol) in Cream B resulted in a clearly demonstrated moisturising effect as expected. Unexpectedly though, the effect was also long lasting.

Table 1. Skin moisturisation.

| | Comparison | Moisturisation |
|----|---------------------|------------------|
| 30 | Cream A (no active) | day 0 vs. day 15 |
| | | day 0 vs. day 16 |
| | Cream B (glycerol) | day 0 vs. day 15 |
| | | day 0 vs. day 16 |
| 35 | Cream C (glycerol) | day 0 vs. day 15 |
| | | day 0 vs. day 16 |
| | | day 0 vs. day 17 |
| | | |

* = $p < 0.1$ ** = $p < 0.05$

Table 2. Skin roughness.

| | Comparison | Smoothing |
|-------------------------|------------------|-----------|
| 5 Cream C (glycerol) | day 0 vs. day 15 | +6.3 %* |
| | day 0 vs. day 16 | +6.6 %** |
| | day 0 vs. day 17 | +3.3 %* |

* = $p < 0.1$ ** = $p < 0.05$

10

The sustained effect found for Cream B was even more pronounced for Cream C which contained a higher content of the galactolipid based emulsifier. Conventional creams containing glycerol have not been reported to exhibit any sustained moisturising effect at all. The results presented in Table 1 and 2 clearly and surprisingly demonstrate a moisturising as well as a smoothing effect which last for at least three days after the last application.

15

CLAIMS

1. A topical formulation of the oil-in-water emulsion type, in which a variety of pharmaceutical or cosmetic compounds can be incorporated, comprising an oily material, an emulsifier and an aqueous phase, wherein the emulsifier is a glycolipid based material, and which after application on the skin gives a sustained local effect of the incorporated compound.
2. A topical formulation according to claim 1, comprising 0.1-50 % by weight oily material and 0.5-20 % by weight galactolipid emulsifier.
3. Use of a topical formulation of the oil-in-water type comprising an oily material, an aqueous phase and an emulsifier, wherein the emulsifier is a galactolipid material, as a carrier for providing a sustained effect of an incorporated active substance.
4. Use according to claim 3, wherein the topical formulation comprises 0.1-50 % by weight oily material, preferably 1-40 %, and 0.5-20 % by weight emulsifier.
5. Use according to claim 3 or 4, wherein the galactolipid material consists of at least 50 % by weight digalactosyldiacylglycerols and a remainder of other polar lipids, preferably in an amount of 1.0-5.0 % by weight.
6. Use according to any of claims 3-5, wherein the galactolipid material consists of 50-70 % by weight digalactosyldiacylglycerols and 30-50 % other polar lipids.
7. Use according to claim 3 or 4, wherein the galactolipid material is a fractionated oat oil which contains 10-90 % by weight polar lipids and a remainder

of non-polar lipids, preferably in an amount of 2.0-10 % by weight.

8. Use according to any of claims 3, 4 and 7, wherein the galactolipid material is a fractionated oat oil which contains 40-60 % by weight polar lipids and a remainder of non-polar lipids.

9. Use according to any of claims 3-8, wherein the active substance is a pharmacologically active substance.

10. Use according to any of claims 3-8, wherein the active substance is a cosmetological substance.

11. Use according to any of claims 3-8, wherein the active substance is a moisturiser.

12. Topical cream base giving an incorporated substance a sustained effect, comprising in % by weight

| | |
|-------------------------|-------------|
| Oily material | 10.0-30.0 % |
| Galactolipid emulsifier | 0.5-5 % |
| Thickener | 2.0-10.0 % |
| Preservative | 0.1-1.0 % |
| Water | ad 100 % |

13. Topical formulation having a sustained moisturising effect, comprising in % by weight

| | |
|-------------------------|-------------|
| Glycerol | 1.0-5.0 % |
| Oily material | 10.0-30.0 % |
| Galactolipid emulsifier | 0.5-5 % |
| Thickener | 2.0-10.0 % |
| Preservative | 0.1-1.0 % |
| Water | ad 100 % |

14. Topical formulation having a sustained anti-inflammatory effect, comprising in % by weight

| | | |
|---|-------------------------|-------------|
| | Hydrocortisone | 0.5-1.5 % |
| | Oily material | 10.0-30.0 % |
| 5 | Galactolipid emulsifier | 0.5-5 % |
| | Thickener | 2.0-10.0 % |
| | Preservative | 0.1-1.0 % |
| | Water | ad 100 % |

10 15. Topical formulation having a sustained anti-psoriatic effect, comprising in % by weight

| | | |
|----|--------------------------|-------------|
| | 13-hydroxy-linoleic acid | 0.001-0.1 % |
| | Oily material | 10.0-30.0 % |
| | Galactolipid emulsifier | 0.5-5 % |
| 15 | Thickener | 2.0-10.0 % |
| | Preservative | 0.1-1.0 % |
| | Water | ad 100 % |

20

25

30

35

ABSTRACT

The invention relates to the use of a topical formulation of the oil-in-water type comprising an oily material, an aqueous phase and an emulsifier, wherein
5 the emulsifier is a galactolipid material, as a carrier for providing a sustained effect of an incorporated active substance.

New topical formulations are also described.

THIS PAGE BLANK (USPTO)